| Autor: |
Zeng, Zheng, Li, Fangyuan, Zhong, Mingli, Zhu, Ling, Chen, Wei, Wang, Xiaotao |
| Zdroj: |
Clinics; January-December 2024, Vol. 79 Issue: 1 |
| Abstrakt: |
•In the present study, the authors found a new antiviral drug-azvudinea used in patients with hematological malignancies, is as effective and safe as the well-known nematve-litonavir.•There have been few clinical trials using azvudine to date, the present study may serve as a suggestion that the treatment was effective.•In the present study the authors found that anti-SARS-CoV-2 vaccines show significantly less robust efficacy in eliciting an immune response in HM patients than observed in the general population, suggesting that vaccination may be of little value in HM patients.•In the present study, the authors found a new antiviral drug-azvudinea used in patients with Hematological Malignancies (HM), is as effective and safe as the well-known nematve-litonavir. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
